News about Clinical Trials

Arrowhead Reports Interim Phase 1/2a Data for ARO-MAPT

Arrowhead Pharmaceuticals has reported interim phase 1/2a ARO-MAPT data showing deep, durable tau reductions in healthy volunteers.

Clinical Trials | 15/10/2026 | By News Bureau

Bristol Myers Squibb Reports Positive RYZ101 Phase 3 Results

Bristol Myers Squibb reports positive interim results from the Phase 3 ACTION-1 trial of investigational radiopharmaceutical therapy RYZ101 in patients with GEP-NETs.

Clinical Trials | 14/10/2026 | By News Bureau

Uganda Launches Phase I Trial of Bundibugyo Ebola Vaccine

Uganda has launched a Phase I trial of Oxford’s Bundibugyo Ebola vaccine candidate, with Serum Institute of India supplying investigational doses to support clinical evaluation and global epidemic preparedness.

Clinical Trials | 14/10/2026 | By News Bureau

Orum Therapeutics Doses First Patient in ORM-1153 Trial

Orum Therapeutics has dosed the first patient in its phase 1 ORM-1153 trial for relapsed or refractory AML and other CD123-expressing blood cancers.

Clinical Trials | 14/10/2026 | By News Bureau

AbbVie Reports Phase 3 Skyrizi Data for Crohn's Disease

AbbVie has presented new phase 3 AFFIRM data showing clinical and endoscopic outcomes with subcutaneous SKYRIZI (risankizumab-rzaa) in patients Crohn's Disease.

Clinical Trials | 14/10/2026 | By News Bureau

Life Biosciences Reports First Human Data for ER-100 Trial

Life Biosciences has announced first-in-human data from ongoing phase 1 trial evaluating ER-100 in optic neuropathies.

Clinical Trials | 13/10/2026 | By News Bureau

Neurosterix Completes Phase 1 Studies of NTX-253 for Schizophrenia

Neurosterix has completed Phase 1 studies of NTX-253 and plans to begin Phase 2 development; Addex retains a 20 percent equity interest in the company.

Clinical Trials | 09/10/2026 | By News Bureau

argenx Updates Phase 3 UNITY Trial of Efgartigimod

argenx plans to stop its phase 3 UNITY study of efgartigimod SC in Sjögren’s disease following an IDMC recommendation based on interim analysis.

Clinical Trials | 09/10/2026 | By News Bureau |  118

Transcripta Bio and Synfini Target Huntington's Disease Driver

Transcripta Bio and Synfini use AI-driven chemistry and transcriptome-scale biology to identify a validated Huntington’s disease lead candidate in weeks.

Clinical Trials | 09/10/2026 | By News Bureau |  123

ArriVent's FURVENT Phase 3 Trial Misses Primary PFS Endpoint

ArriVent’s FURVENT Phase 3 trial of firmonertinib in EGFR exon 20 insertion-mutant NSCLC did not meet its primary PFS endpoint.

Clinical Trials | 07/10/2026 | By News Bureau